This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by BAGDADE, J. D. Articles by SUBBAIAH, P. V. Search for Related Content PubMed PubMed Citation Articles by BAGDADE, J. D. Articles by SUBBAIAH, P. V.

Effects of Estropipate Treatment on Plasma Lipids and Lipoprotein Lipid Composition in Postmenopausal Women

Department of Medicine, Section of Endocrinology and Metabolism, Rush Medical College Chicago, Illinois 60612

Address all correspondence and requests for reprints to: John D. Bagdade, M.D., Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, Chicago, Illinois 60612.

It is generally believed that the cardioprotective benefit of long term treatment of postmenopausal women with estrogen results in part from its capacity to increase high density lipoprotein (HDL) and lower low density lipoprotein (LDL) concentrations. The extent to which the various estrogens employed in replacement treatment affect the composition of lipoproteins, however, is not known. For this reason, we have examined the impact of one such preparation, the synthetic estrone estropipate (1.25 mg/day), on lipoprotein levels and composition in six postmenopausal women. After 6 months of treatment, whole plasma triglyceride (pretreatment, 135 ± 63; posttreat-ment, 143 ± 56 mg/dL), cholesterol (pretreatment, 232 ± 14; posttreatment, 216 ± 29 mg/dL), and HDL-C (pretreatment, 57.8 ± 14.8; posttreatment, 55.6 ± 13.2) were unchanged. However, plasma free (unesterified) cholesterol (FC) fell (pretreatment, 73.4 ± 6.2; posttreatment, 53.7 ± 9.3 mg/dL; P < 0.05) and lecithin (L) rose significantly (pretreatment, 2.12 ± 0.29; posttreatment, 2.47 ± 0.34 µmol/mL; P < 0.01). The consequence of these changes was a significant decline in the plasma FC/L ratio (pretreatment, 0.91 ± 0.17; posttreatment, 0.68 ± 0.12; P < 0.01) to levels observed in healthy menstruating women. The calculated lipoprotein particle size was unchanged in very low density lipoproteins and increased significantly (P < 0.05) in LDL after estropipate therapy. Since qualitatively altered lipoproteins enriched in FC and an increased FC/L ratio in plasma are both associated with increased coronary risk, the improvement noted in these parameters after estropipate therapy indicates that its use may be beneficial despite the lack of change in whole plasma lipids.